Sinopharm Accord released its 2026 interim report, showing first-half net profit attributable to the parent of 606 million yuan, down 8.97% year on year. Operating revenue was 36.266 billion yuan, down 1.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 599 million yuan, down 6.8% year on year. Net operating cash flow was negative 1.519 billion yuan, down 10,180.0% year on year. Earnings per share were 0.99 yuan. In the second quarter, operating revenue was 18.44 billion yuan, down 0.3% year on year, and net profit attributable to the parent was 319 million yuan, down 5.7% year on year. As of the end of the second quarter, total assets were 48.171 billion yuan, down 1.9% from the end of the previous year, while net assets attributable to the parent were 18.873 billion yuan, up 1.4% from the end of the previous year. The company said that due to pharmaceutical industry policy adjustments and intensifying market competition, operations faced pressure, but through structural optimization and refined management, the declines in revenue and profit narrowed. The distribution business segment achieved operating revenue of 26.539 billion yuan, down 0.91% year on year, with net profit of 460 million yuan, down 4.56% year on year. In the retail business, Sinopharm Holding Guoda Drugstore achieved operating revenue of 10.227 billion yuan, down 2.40% year on year, as a lower sales mix of high-margin products weighed on profit. In addition, investment income from key associates fell 30.43% year on year, affected by international geopolitical factors and market supply and demand.
China National Accord Medicines Corp LtdFirst-half net profit attributable to parent fell 8.97% to 606 million yuan and revenue declined 1.4% year on year.
Guoda Drugstore's retail revenue fell 2.40% year on year as a lower sales mix of high-margin products weighed on profit.
